Novo Nordisk's Subscription Strategy to Counter Market Pressures

Novo Nordisk counters revenue decline and Eli Lilly's market lead with a Wegovy subscription model, aiming to lock in patients as it awaits new drug approvals.

Facing intense competition and pricing headwinds, Danish pharmaceutical giant Novo Nordisk is implementing a novel subscription model for its blockbuster weight-loss drug, Wegovy. This strategic pivot comes at a crucial juncture for the company, which is contending with a lowered revenue forecast and a significant decline in its share price.

Financial Headwinds and Competitive Landscape

The shift in distribution strategy unfolds against a challenging financial backdrop. Management anticipates a currency-adjusted revenue decline of between 5% and 13% for the 2026 fiscal year. This projection is primarily attributed to new pricing agreements with the U.S. government and reduced reimbursement from public health programs. The market has reacted to these developments, with Novo Nordisk's stock losing approximately 43% over a one-year period and trading near its 52-week low. A modest consolation for shareholders is the upcoming dividend of $1.2751 per share, scheduled for payout on April 8.

Competitive pressure is a key driver for change. Rival Eli Lilly now commands over 60% of the U.S. market for obesity medications. Internationally, expiring patents and lower-cost generic alternatives are squeezing the Danish firm. In a direct response to a flood of copycat drugs in India, Novo Nordisk slashed prices for Wegovy and Ozempic by nearly half at the beginning of April.

The Subscription Model: Locking in Patients

Rather than enacting broad list-price reductions, Novo Nordisk aims to secure long-term patient loyalty through its new subscription plan. Since late March, U.S. patients have been able to sign up for three, six, or twelve-month subscriptions for the Wegovy injection and the newer tablet form via telehealth providers such as WeightWatchers and Ro. An annual commitment costs $249 per month. According to the company, this represents an annual saving of $1,200 for injection users compared to monthly single purchases.

This approach carries clear strategic logic. The tablet version, in particular, is attracting first-time users who were previously reluctant to use injections. The subscription framework is designed to retain these customers within the Novo Nordisk ecosystem before additional rival products gain traction.

Future Hopes Rest on Pipeline Innovation

With current pricing under pressure, the company's future prospects increasingly hinge on its next generation of medications. The combination drug CagriSema has already been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of obesity. A regulatory decision on its approval is expected around the turn of the year 2026/2027. Until the capital markets day in September 2026, this remains the most significant concrete milestone for the firm's operational development.